Day(s)
:
Hour(s)
:
Minute(s)
:
Second(s)
OVERVIEW
As healthcare systems evolve, Pharmacoeconomics will remain a key discipline for guiding decisions that optimize outcomes, resource allocation, and the overall sustainability of healthcare.
The MEPDPS 2024: Middle East Pharmacoeconomics and Drug Policy Summit 2024 will take place on 23-24 February at JW Marriott Hotel Marina, Dubai, UAE and has been meticulously crafted to serve as a dynamic platform for thought leaders, policymakers, and key stakeholders to exchange insights, share experiences, in the areas focused on healthcare policy, the HEOR in healthcare decision making, economic evaluations, VBHC, the implications of HTA, responses to Real-World Evidence, collaboration, affordability, and equity in healthcare, that enhance patient outcomes, ensure accessibility to innovative therapies, and contribute to the sustainability of our healthcare infrastructure.
Who Attended 2023 Summit
Conference Key Facts
WHO SHOULD ATTEND
- Regulatory authorities
- Pharmacoeconomists
- Health Economists
- Health Technology Assessment Specialists
- Payers
- Healthcare providers
- Pharma industry
- Pharmacists and more
KEY BENEFITS OF ATTENDING
- Highlight future opportunities and challenges in developing the healthcare and research economy in the GCC countries
- Discuss the novel approaches to value assessment, achieving cost effective healthcare solutions and access to innovative medicines in the GCC
- Understanding the principles of outcome based healthcare and evidence based medication
- Reviewing pharmacoeconomics and outcomes research strategies
- Exploring the real world data, the burden of disease and HTA to make proper assessments and support decision making
Summit chairman
Ahmed Al Jedai
Scientific Committee Chair
Hajer Al-Mudaiheem
Pharm.D., MSc. Clinical pharmacy, CLSSBB Advisor, Assistant Deputy for Therapeutic Supportive Services, Director, Drug Policy and Regulation Department Ministry of Health, KSA
Strategic Partner
Scientific Committee Members
Ahmed Al Jedai
Founding President, Saudi Society of Clinical Pharmacy, Professor, Colleges of Medicine and Pharmacy, Alfaisal University, Consultant Clinical Pharmacist, Solid Organ Transplant, Ministry of Health, KSA
Ahmed Seyam
Director: Health Economics Health Systems Research – UHIA , Health Economics, Health Systems Healthcare Financing Consultant & MoHP, MoF, Cairo, Egypt
Anas Hamad
PhD, MSc, DMS, BPharm, RPh, Director of Pharmacy Department, National Center for Cancer Care & Research; Assistant Professor, College of Pharmacy, Qatar University, Qatar
Fabrizio Gianfrate
Full Professor of Health Economics and Outcome Research, University of Ferrara and LUISS Business School Rome, Italy
Hajer Al-Mudaiheem
Pharm.D., MSc. Clinical pharmacy, CLSSBB Advisor, Assistant Deputy for Therapeutic Supportive Services, Director, Drug Policy and Regulation Department Ministry of Health, KSA
Ibrahim Alrashdi
Director General of Medical Supplies, Ministry of Health, Oman
Mohammed Alluhidan
Head of the Health Economics Unit, The Saudi Health Council, KSA
Mouna Jameleddine
Director of HTA Department of INEAS (Tunisia); Former Vice-Chair of INAHTA (International Network of Agencies for HTA); Former Chair of the ISPOR HTA RoundTable for Middle East and Africa
Sara Al Dallal
MBBS, MSc, President, Emirates Health
Economics Society, Emirates Medical Association; Senior Health Service Specialist, Dubai Health Authority, UAE
Summit Packages
2-Days Summit Access
Physicians, Regulatory Authorities, Health Economists, Hospital and Community Pharmacists
Pharmaceutical Companies and Vendors
Early Bird Rate is valid until 15 February only
for Group Registration
Please contact: +971 4 361 9616